Evidence map›Paper›PMID 41019040›Full record

ArticleFrontiers in immunology2025

Correction: Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer.

Hans-Heinrich Oberg, Malte Deseke, Steffen Krohn, Dorothee Winterberg, Matthias Peipp, Dirk Bauerschlag, Klaus-Peter Künkele, Daniela Wesch, Christoph Baumann

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Hans-Heinrich Oberg *Institute of Immunology, University Hospital Schleswig-Holstein, Kiel, Germany.
Malte Deseke *Evobright GmbH, Vienna, Austria.
Steffen Krohn *Division of Antibody-Based Immunotherapy, University Hospital Schleswig-Holstein and Christian-Albrechts University, Kiel, Germany.
Dorothee WinterbergDivision of Antibody-Based Immunotherapy, University Hospital Schleswig-Holstein and Christian-Albrechts University, Kiel, Germany.
Matthias PeippDivision of Antibody-Based Immunotherapy, University Hospital Schleswig-Holstein and Christian-Albrechts University, Kiel, Germany.
Dirk BauerschlagPolyclinic and Clinic of Gynecology, University Center, Jena, Germany.
Klaus-Peter KünkeleEvobright GmbH, Vienna, Austria.
Daniela WeschInstitute of Immunology, University Hospital Schleswig-Holstein, Kiel, Germany.
Christoph BaumannEvobright GmbH, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2025.1628501.].

Indexed as

BTN3AevobodyFOLR1immunotherapyovarian cancerVγ9Vδ2 T cells

Identifiers

PMID41019040
PMCPMC12464414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.